Ignite Creation Date:
2024-05-06 @ 8:16 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06313086
Status:
RECRUITING
Last Update Posted:
2024-05-10
First Post:
2024-03-01
Brief Title:
DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
Sponsor:
CSPC ZhongQi Pharmaceutical Technology Co Ltd
Organization:
CSPC ZhongQi Pharmaceutical Technology Co Ltd
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-03-13
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-02
Completion Date Type:
ESTIMATED
First Submit Date:
2024-03-01
First Submit QC Date:
March 14 2024
Study First Post Date:
2024-03-15
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-05-08
Last Update Post Date:
2024-05-10
Last Update Post Date Type:
ACTUAL